Pasritamig Shows Strong Phase 1b Results in mCRPC
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
Immunotherapy
Advertisement
H&N Cancer Market to Reach $2.6B by 2032
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
VRON-0200 Shows Durable Immunity in HBV Trial
PHILADELPHIA, Feb. 22, 2026 — Virion Therapeutics reported new Phase 1b clinical data at the 33rd Conference on Retroviruses...
Analgesic Allergy Labels Tied to Maternal Risks
MILWAUKEE, Feb. 21, 2026 — New research presented at the 2026 Annual Meeting of the American Academy of Allergy,...
ImmunityBio Expands ANKTIVA Access in Saudi Arabia
SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional...
Advertisements
RYBREVANT FASPRO Shows 56% Response in HNSCC
RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...
Ficerafusp Alfa Shows Strong Responses in HNSCC
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
Agenus BOT+BAL Biomarkers Improve Survival in MSS mCRC
LEXINGTON, Mass., Feb. 19, 2026 — Agenus Inc. announced new translational and clinical biomarker findings demonstrating survival stratification in...
EU Clears ANKTIVA–BCG for Bladder Cancer Therapy
Conditional Approval Expands Access to 33 Countries February 18, 2026 | Culver City, California ImmunityBio announced that the European...
TuHURA Files IND for TBS-2025 in AML Trial
TAMPA, FLORIDA, UNITED STATES — February 17, 2026 TuHURA Biosciences has filed an Investigational New Drug (IND) application with...
Advertisement
